Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
4 authors.
Stephanie N ShishidoConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA 90089, USA.
George CourcoubetisConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA 90089, USA.
Peter KuhnConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA 90089, USA.ORCID 0000-0003-2629-4505
Jeremy MasonConvergent Science Institute in Cancer, Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA 90089, USA.ORCID 0000-0002-5933-5003
Funding
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Multi-modal Liquid Biopsy Early Assessment of Breast Cancer, Pancreatic Cancer, and Multiple MyelomaU01CA285013 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KUHN, PETER · 2023 to 2025
$3.4M
Adelson Foundation 013694-00001Breast Cancer Research Foundation BCRF-23-089Epic Sciences (United States) Sponsored Research AgreementHart Family Research Fund Institutional SupportMing Hsieh Institute for Research on Engineering-Medicine for Cancer N/ANCI NIH HHS P30 CA014089NCI NIH HHS U01 CA285013NCI NIH HHS U01CA285013USC Michelson Center Convergent Science Institute in Cancer Institutional SupportUSC Norris Comprehensive Cancer Center 5P30CA014089-40Vassiliadis Research Fund Institutional Support
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Automated Single-Cell Analysis in the Liquid Biopsy of Breast Cancer. · full record | Socratic